Alan J Russell sold $7.9M of EWTX
Chief Scientific Officer at Edgewise Therapeutics, Inc.. 200,000 shares at an average of $39.41, traded Jul 1, 2026, filed Jul 2, 2026.
Score components
- +15RoleOfficer
- +25Trade size$7.9M at market
- +20Share of holdings soldSold 89% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001853529-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | MOption exercise Common Stock10b5-1 | +130,352 | $0.45 | $59k | 154,907 | Jul 2, 2026 |
| Jul 1, 2026 | MOption exercise Common Stock10b5-1 | +69,648 | $0.18 | $13k | 224,555 | Jul 2, 2026 |
| Jul 1, 2026 | SOpen-market sale Common Stock10b5-1 | -130,352 | $39.41 | $5.1M | 94,203 | Jul 2, 2026 |
| Jul 1, 2026 | SOpen-market sale Common Stock10b5-1 | -69,648 | $39.41 | $2.7M | 24,555 | Jul 2, 2026 |
| Jul 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -130,352 | $0.00 | $0 | 0 | Jul 2, 2026 |
| Jul 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -69,648 | $0.00 | $0 | 1,077,717 | Jul 2, 2026 |
Related signals
Other insiders at Edgewise Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | Edgewise Therapeutics, Inc. | Behrad Derakhshan Chief Business Officer | $223k 5,100 shares | -14% | |
| 31Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $413k 9,441 shares | -52% | |
| 57Moderate | Edgewise Therapeutics, Inc. | Kevin Koch President and CEO | $785k 17,971 shares | -26% | |
| 32Weak | Edgewise Therapeutics, Inc. | John R Moore General Counsel | $220k 5,016 shares | -22% | |
| 33Weak | Edgewise Therapeutics, Inc. | Alan J Russell Chief Scientific Officer | $258k 5,901 shares | -16% | |
| 25Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $2.1M 55,230 shares | -575% | |
| 24Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $926k 28,662 shares | -75% | |
| 21Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $685k 21,338 shares | -69% | |
| 33Weak | Edgewise Therapeutics, Inc. | Joanne M. Donovan CMO | $507k 16,358 shares | -63% | |
| 25Weak | Edgewise Therapeutics, Inc. | Badreddin Edris director | $3.4M 115,471 shares | -85% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.